Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic

Khaldoun G Tarakji1, Richard Brunken, Patrick M McCarthy

  • 1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

Circulation
|January 5, 2006
PubMed

Insights

Early revascularization in severe systolic heart failure patients may improve survival. Positron emission tomography with fluorodeoxyglucose (PET/FDG) imaging helps identify suitable candidates for this life-saving intervention.

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Medical Imaging

Background:

  • The clinical benefit of revascularization in severe systolic heart failure remains uncertain.
  • Positron emission tomography (PET) with fluorodeoxyglucose (FDG) imaging may identify patients who could benefit from revascularization.
  • This study investigates the survival advantage of revascularization in heart failure patients.

Purpose of the Study:

  • To determine if revascularization offers a survival advantage in patients with severe systolic heart failure.
  • To assess the role of PET/FDG imaging in identifying patients who benefit from intervention.
  • To analyze survival outcomes based on early cardiac intervention.

Main Methods:

  • A propensity analysis was conducted on 765 patients with severe systolic heart failure (ejection fraction ≤35%).
  • Patients underwent PET/FDG imaging between 1997 and 2002.
  • Early intervention (within 6 months) was compared to medical treatment using propensity-matched cohorts.

Main Results:

  • Propensity matching identified 153 patients who received early intervention and 153 who did not.
  • Early intervention was associated with a significantly lower risk of death (3-year mortality 15% vs. 35%).
  • The propensity-adjusted hazard ratio for death with early intervention was 0.52 (P=0.0004).

Conclusions:

  • Early intervention in systolic heart failure patients undergoing PET/FDG may improve survival.
  • The survival benefit appears independent of the degree of myocardial viability detected by PET/FDG.
  • PET/FDG imaging can aid in selecting heart failure patients for potentially life-extending revascularization procedures.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...